Jian Shi | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., … Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., … Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023